The Biotron Limited (ASX: BIT) share price is flat today after it revealed its financial results for the quarter ending December 31 2018, but it has been one of the most volatile small-cap businesses in 2018 due to its clinical trials and research into commercialising a treatment for the HIV virus.
According to the company's management team its drug BIT225 is a leading 'best-in-class' orally ingested drug that could help treat patients with HIV and the Hepatitis C virus.
The company's report that its Phase II clinical trials for the drug showed positive data in treating HIV patients sent the share price to as high as 44 cents in October 2018, although the share price now sits back at just 12 cents as the speculative excitement fades in the business.
Today it reported a $1.07 million government research tax incentive refund helped it deliver an operating cash gain of $380,000 for the quarter ending December 31 2018, but it has no revenues and some expensive trials coming up if it's serious about trying to commercialise its BIT225 drug.
The company has a market cap of $71 million today and falls into the speculative, high-risk bucket.
